Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Suma Krishnan Sells 25,000 Shares

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Suma Krishnan also recently made the following trade(s):

• On Friday, December 13th, Suma Krishnan sold 25,000 shares of Krystal Biotech stock. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00.

Krystal Biotech Stock Up 1.1 %

Shares of Krystal Biotech stock opened at $179.38 on Friday. The firm has a market cap of $5.17 billion, a PE ratio of 59.99 and a beta of 0.87. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The business’s fifty day simple moving average is $163.50 and its 200-day simple moving average is $173.90.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech’s revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.30 earnings per share. As a group, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Institutional Trading of Krystal Biotech

Several institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech during the third quarter worth $40,000. Huntington National Bank boosted its holdings in Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after acquiring an additional 283 shares during the period. GF Fund Management CO. LTD. acquired a new position in Krystal Biotech in the 4th quarter valued at about $95,000. KBC Group NV increased its stake in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after purchasing an additional 132 shares during the period. Finally, Covestor Ltd lifted its position in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after purchasing an additional 642 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KRYS. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $220.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).